{
    "clinical_study": {
        "@rank": "100806", 
        "arm_group": [
            {
                "arm_group_label": "Caffeine", 
                "arm_group_type": "Experimental", 
                "description": "Caffeine citrate 6 mg/kg/day"
            }, 
            {
                "arm_group_label": "Active Comparator: no caffeine", 
                "arm_group_type": "No Intervention", 
                "description": "Compare extended use of caffeine citrate 6 mg/kg/day to no caffeine (usual care) in regard to extent of intermittent hypoxia from 35 weeks postmenstrual age (PMA) to 40 weeks PMA."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this pilot study is to document the extent to which intermittent hypoxia\n      persists beyond the age of discontinuing clinical  methylxanthine, and will assess the\n      effect of caffeine treatment on the number of intermittent hypoxia episodes and the total\n      number of seconds with a hemoglobin oxygen saturation (HbO2 SAT) below 90%."
        }, 
        "brief_title": "Effects of Caffeine on Intermittent Hypoxia in Infants Born Preterm", 
        "completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "condition": "Hypoxia", 
        "condition_browse": {
            "mesh_term": "Anoxia"
        }, 
        "detailed_description": {
            "textblock": "Infants with prior clinical treatment with caffeine in the neonatal intensive care unit\n      (NICU) will be enrolled and continuous physiologic data recording of oxygen hemoglobin\n      saturation (HbO2 SAT) and heart rate will begin as early as 33 weeks postmenstrual age\n      (PMA).  Randomization will occur when enrolled infants reach a corrected gestational age of\n      at least 34 weeks PMA AND clinical caffeine has been discontinued for at least 5 days.\n      Infants will be randomized to receive caffeine or to continue with usual care. The group\n      randomized to start caffeine will receive an oral loading dose of caffeine citrate of 20\n      mg/kg on Day #1, followed by a single daily oral maintenance dose of 6 mg/kg starting on Day\n      #2 and continued daily thereafter until 40 weeks PMA. The continuous oximeter recordings\n      will be stopped at the same time.  The number of intermittent hypoxia events/hour per week\n      and the frequency/duration of bradycardia will be compared between the caffeine group and\n      the usual care (no-caffeine) group for each week of physiologic data recordings."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Gestational age of 25 + 0 to 32 + 0 weeks PMA at birth, and 34 + 0 to 375 + 6 weeks\n             PMA at randomization\n\n          2. Prior treatment with caffeine based on routine clinical indications, and clinical\n             caffeine now discontinued \u22655 days before randomization\n\n          3. Previously tolerated clinical treatment with caffeine\n\n          4. Breathing room air (no current supplemental O2 treatment; may have previously\n             required respiratory support)\n\n          5. Parental consent to enroll in pilot study\n\n        Exclusion Criteria:\n\n          1. Congenital syndrome or other medical diagnosis associated with known risk for\n             neurodevelopmental abnormality, including intraventricular hemorrhage Grade 3 or\n             greater, cyanotic congenital heart disease, confirmed central nervous system\n             infection, or fetal alcohol syndrome\n\n          2. Currently receiving supplemental oxygen, ventilatory support, or nasal airflow\n             therapy\n\n          3. Clinical decision to restart caffeine prior to completing 5 days of continuous\n             physiologic monitoring after clinical caffeine stopped\n\n          4. Anticipated inability to meet protocol requirements"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "37 Weeks", 
            "minimum_age": "33 Weeks"
        }, 
        "enrollment": {
            "#text": "105", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01875159", 
            "org_study_id": "ASI 01"
        }, 
        "intervention": {
            "arm_group_label": "Caffeine", 
            "description": "Comparison of caffeine citrate 6 mg/kg/day versus no caffeine (usual care) on extent of intermittent hypoxia at 35, 36, 37, 38, 39, and 40 weeks postmenstrual age.", 
            "intervention_name": "Caffeine citrate 6 mg/kg/day", 
            "intervention_type": "Drug", 
            "other_name": "Cafcit"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Caffeine", 
                "Caffeine citrate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Prematurity", 
            "Apnea of prematurity", 
            "Intermittent hypoxia"
        ], 
        "lastchanged_date": "June 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20814"
                }, 
                "name": "Uniformed Services University of Health Sciences"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pilot Study of Effects of Caffeine on Intermittent Hypoxia in Infants Born Preterm", 
        "overall_official": {
            "affiliation": "American SIDS Instittute", 
            "last_name": "Betty McEntire, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Intermittent hypoxia: number of episodes per hour of pulse oximeter recording of oxygen saturation to less than 90%, and sec/hour of recording to less than 90%.", 
            "measure": "Episodes and seconds/hour of intermittent hypoxia", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 40 weeks postmenstrual age"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01875159"
        }, 
        "responsible_party": {
            "investigator_affiliation": "American SIDS Institute", 
            "investigator_full_name": "Carl Hunt", 
            "investigator_title": "Research Professor of Pediatrics", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "American SIDS Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "American SIDS Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}